- B cells regulate T cell transfer colitis by partially reconstituting luminal IgA and modulating the colonic microbiota. [Journal Article]Inflamm Bowel Dis. 2026 Oct 12. [Online ahead of print]IB
- Loss of immune tolerance to commensal microbial antigens is a central driver of inflammatory bowel disease. While regulatory T cells are well recognized in maintaining intestinal homeostasis, the contribution of B cells-particularly IgA-secreting cells-remains incompletely defined. In the T cell transfer colitis model, cotransfer of splenic B cells attenuates disease, an effect largely attributed…
- Publisher Full Text (DOI)
- Morganella morganii-derived histamine impairs intestinal barrier function via HRH4 and aggravates colitis. [Journal Article]Inflamm Bowel Dis. 2026 Oct 09. [Online ahead of print]IB
- CONCLUSIONS: These findings suggest a previously unrecognized pathway in which the diet-responsive pathobiont M. morganii may impair epithelial barrier integrity through histamine-HRH4 signaling. Targeting histamine synthesis and HRH4 may offer a potential therapeutic avenue worth further investigation.
- Publisher Full Text (DOI)
- Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis. [Journal Article]Inflamm Bowel Dis. 2026 Oct 08. [Online ahead of print]IB
- CONCLUSIONS: Relative efficacy of advanced therapies in luminal CD varied by disease location. These findings support consideration of disease location in personalized treatment decision-making to improve clinical outcomes.
- Publisher Full Text (DOI)
- Current evidence for first-line advanced therapies in pediatric ulcerative colitis: a critical review. [Journal Article]Inflamm Bowel Dis. 2026 Oct 08. [Online ahead of print]IB
- CONCLUSIONS: Current pediatric evidence supports the efficacy of multiple advanced therapies and has characterized important safety outcomes; however, evidence establishing therapeutic efficacy should be distinguished from evidence directly informing first-line treatment selection. Future pediatric research should increasingly generate comparative and predictive evidence that informs which effective advanced therapy should be selected first and for whom.
- Publisher Full Text (DOI)
- Enterotype-based stratification identifies clinically distinct microbial subtypes in inflammatory bowel disease. [Journal Article]Inflamm Bowel Dis. 2026 Oct 05. [Online ahead of print]IB
- CONCLUSIONS: Gut microbial enterotypes are associated with distinct clinical phenotypes and treatment escalation in IBD, and exhibit enterotype-specific microbial community structures and alterations across disease states. Enterotype-based stratification may provide a clinically relevant framework for assessing risk assessment and guiding personalized disease management.
- Publisher Full Text (DOI)
- Comparative effectiveness and safety of upadacitinib versus vedolizumab in anti-TNF-exposed patients with ulcerative colitis. [Journal Article]Inflamm Bowel Dis. 2026 Sep 30. [Online ahead of print]IB
- CONCLUSIONS: Upadacitinib demonstrates superior effectiveness over vedolizumab in anti-TNF-exposed UC but carries a higher burden of adverse events, highlighting the need for personalized benefit-risk assessment to guide treatment selection.
- Publisher Full Text (DOI)
- Postoperative weight trajectories after ileal pouch-anal anastomosis are associated with the development of Crohn's-like disease of the pouch. [Journal Article]Inflamm Bowel Dis. 2026 Sep 29. [Online ahead of print]IB
- Publisher Full Text (DOI)
- Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study). [Journal Article]Inflamm Bowel Dis. 2026 Sep 28. [Online ahead of print]IB
- CONCLUSIONS: In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8 weeks of treatment. Continued treatment for up to 16 weeks may improve symptoms, even in patients with insufficient response at week 8.
- Publisher Full Text (DOI)
- Handheld intestinal ultrasound and the point-of-care question in pediatric IBD: a commentary. [Journal Article]Inflamm Bowel Dis. 2026 Sep 28. [Online ahead of print]IB
- Responding to Miyatani et al., this commentary, focused on the United States. We contend that handheld intestinal ultrasound reframes the point-of-care debate regarding timing and cost, not diagnostic superiority. For many pediatric inflammatory bowel disease programs, bridging with radiology while building training and governance remains the wisest near-term approach.
- Publisher Full Text (DOI)
- Fecal calprotectin changes after polyethylene glycol bowel preparation in patients with ulcerative colitis in remission. [Journal Article]Inflamm Bowel Dis. 2026 Sep 26. [Online ahead of print]IB
- This prospective paired-sample study evaluated fecal calprotectin changes after polyethylene glycol-based bowel preparation in ulcerative colitis patients in remission. Calprotectin increased modestly, particularly in patients with Mayo 1 endoscopic subscore, but clinical worsening was uncommon and healthy individuals showed no significant change.
- Publisher Full Text (DOI)